Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

Messoud Ashina, Joel Saper, Roger Cady, Barbara A Schaeffler, David M Biondi, Joe Hirman, Susan Pederson, Brent Allan, Jeff Smith, Messoud Ashina, Joel Saper, Roger Cady, Barbara A Schaeffler, David M Biondi, Joe Hirman, Susan Pederson, Brent Allan, Jeff Smith

Abstract

Objective: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine.

Methods: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy-1 (PROMISE-1) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with episodic migraine were randomized to eptinezumab 30 mg, 100 mg, 300 mg, or placebo for up to four intravenous (IV) doses administered every 12 weeks. The primary endpoint was change from baseline in monthly migraine days (MMDs) over weeks 1-12.

Results: A total of 888 patients received treatment across 84 study sites. Mean MMDs at baseline was ∼8.6 across treatment groups. Eptinezumab 100 mg and 300 mg met the primary endpoint, significantly reducing MMDs across weeks 1-12 compared with placebo (30 mg, -4.0; 100 mg, -3.9, p = 0.0182; 300 mg, -4.3; placebo, -3.2, p = 0.0001). Treatment-emergent adverse events were reported by 58.4% (30 mg), 63.2% (100 mg), 57.6% (300 mg), and 59.5% (placebo) of patients. Treatment-emergent adverse events reported by ≥2% of eptinezumab-treated patients at an incidence greater than placebo included: upper respiratory tract infection (30 mg, 11.4%; 100 mg, 9.9%; 300 mg, 10.3%; placebo, 7.2%), and fatigue (30 mg, 2.3%; 100 mg, 3.6%; 300 mg, 3.6%; placebo, <1%).

Conclusion: Eptinezumab (100 mg or 300 mg) significantly reduced migraine frequency, was well tolerated, and had an acceptable safety profile when used for the preventive treatment of migraine in adults with episodic migraine. ClinicalTrials.gov identifier: NCT02559895.

Keywords: ALD403; Eptinezumab; efficacy; episodic migraine; safety.

Figures

Figure 1.
Figure 1.
Decision rule for dose levels (primary and key secondary endpoints). aStatistical significance must have been met to proceed to the next test within each series. bTo proceed to the next series, all tests in the previous series must have shown a statistically significant difference from placebo.
Figure 2.
Figure 2.
Patient disposition. ICF: informed consent form; PK: pharmacokinetics.
Figure 3.
Figure 3.
Primary endpoint: Change from baseline to week 12 in mean monthly migraine days (full analysis population). aNot statistically significant per the testing hierarchy; unadjusted p-value presented.
Figure 4.
Figure 4.
Key secondary endpoints: (a) ≥75% migraine responder rates and (b) ≥50% migraine responder rates (full analysis population). aNot statistically significant per the testing hierarchy; unadjusted p-value presented.

References

    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–1159.
    1. Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71: 559–566.
    1. McLean G, Mercer SW. Chronic migraine, comorbidity, and socioeconomic deprivation: Cross-sectional analysis of a large nationally representative primary care database. J Comorb 2017; 7: 89–95.
    1. Minen MT, Begasse De Dhaem O, Kroon Van Diest A, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 2016; 87: 741–749.
    1. Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 2015; 35: 563–578.
    1. Adelborg K, Szepligeti SK, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ 2018; 360: k96–k96.
    1. Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: Prospective cohort study. BMJ 2016; 353: i2610–i2610.
    1. Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ 2009; 339: b3914–b3914.
    1. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54–61.
    1. Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 2010; 30: 1179–1186.
    1. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010; 6: 573–582.
    1. Zhu Y, Liu Y, Zhao J, et al. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: A meta-analysis. Neurol Sci 2018; 39: 2097–2106.
    1. Raffaelli B, Reuter U. The biology of monoclonal antibodies: Focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics 2018; 15: 324–335.
    1. Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis. Clin Neurol Neurosurg 2017; 154: 74–78.
    1. Khan S, Olesen A, Ashina M. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia 2019; 39: 374–389.
    1. Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017; 377: 2123–2132.
    1. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017; 377: 2113–2122.
    1. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: The evolve-1 randomized clinical trial. JAMA Neurol 2018; 75: 1080–1088.
    1. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38: 1442–1454.
    1. Dodick D, Ashina M, Kudrow D, et al. A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: Primary results of the ARISE trial. J Neurol Neurosurg Psychiatry 2017; 88: e1.63. –e1.63. .
    1. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. JAMA 2018; 319: 1999–2008.
    1. Baker B, Schaeffler B, Cady R, et al. Rational design of a monoclonal antibody (mAB) inhibiting calcitonin gene-related peptide (CGRP), ALD403, intended for the prevention of migraine (p2.155). Neurology 2017; 88 .
    1. Latham J, Karasek C, Ojala E, et al. Characterization of the intrinsic binding features of three anti-CGRP therapeutic antibodies effective in preventing migraine: A comparative pre-clinical case study of ALD403, LY-2951742, TEV-48125 (PS74LB). In: 58th Annual Scientific Meeting American Headache Society, Marriott Marquis San Diego Marina, San Diego, CA, 9–12 June 2016; 56: 1398–1398.
    1. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014; 13: 1100–1107.
    1. Dodick DW, Lipton RB, Goadsby PJ, et al. A single intravenous administration of ALD403 (eptinezumab) reduces use of triptans among patients with chronic migraine (oral presentation). Cephalalgia 2017; 37(1 Suppl): 16–16.
    1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004; 24: 9–160.
    1. Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale (C-SSRS). Columbia University, (14 January 2009, accessed 2 October 2015).
    1. U.S. Department of Health and Human Services – Food and Drug Administration. Multiple endpoints in clinical trials – guidance for industry. Draft Guidance, January 2017, (accessed 27 January 2020).
    1. Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 2019; 39: 1075–1085.
    1. Saper JR, Lipton RB, Kudrow DB, et al. Primary results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) trial: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraines (S20.001). Neurology 2018; 90. .
    1. US Food and Drug Administration. US Food and Drug Administration (FDA) Immunogenicity testing of therapeutic protein products – developing and validating assays for anti-drug antibody detection – guidance for industry, (2019, accessed 20 December 2019).
    1. Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014; 16: 658–673.
    1. Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: The clinical evidence to date. Clin Pharmacol Drug Dev 2017; 6: 534–547.
    1. Amgen, Inc. AIMOVIG (package insert). Thousand Oaks, CA: Amgen Inc., 2019.
    1. Eli Lilly and Company. EMGALITY (package insert). Indianapolis, IN: Eli Lilly and Company, 2018.
    1. Teva Pharmaceuticals USA. AJOVY (package insert). North Wales, PA: Teva Pharmaceuticals USA, 2019.
    1. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine, 3rd edition. A guide for investigators. Cephalalgia 2012; 32: 6–38.
    1. Couch JR., Jr Placebo effect and clinical trials in migraine therapy. Neuroepidemiology 1987; 6: 178–185.
    1. Pollo A, Amanzio M, Arslanian A, et al. Response expectancies in placebo analgesia and their clinical relevance. Pain 2001; 93: 77–84.
    1. Antonaci F, Chimento P, Diener HC, et al. Lessons from placebo effects in migraine treatment. J Headache Pain 2007; 8: 63–66.
    1. de Craen AJ, Tijssen JG, de Gans J, et al. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 2000; 247: 183–188.
    1. Dalakas MC, Rakocevic G, Dambrosia JM, et al. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol 2017; 82: 271–277.
    1. Kam-Hansen S, Jakubowski M, Kelley JM, et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med 2014; 6: 218ra5–218ra5.
    1. Benedetti F. Placebo effects: From the neurobiological paradigm to translational implications. Neuron 2014; 84: 623–637.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner